Better Coronavirus Stock: Gilead Sciences vs. Sorrento Therapeutics
Drugmakers both big and small have jumped into the fray of developing therapies that could treat novel coronavirus disease COVID-19. Even a hint of success have lit a fire beneath the shares of several of these companies so far in 2020.
Two prime examples of this are Gilead Sciences (NASDAQ: GILD) and Sorrento Therapeutics (NASDAQ: SRNE). Gilead has without question delivered more compelling results for its COVID-19 drug remdesivir, but Sorrento has been the bigger year-to-date winner in terms of stock performance.
Which of these coronavirus-focused stocks is the better pick? Here's how Gilead and Sorrento stack up against each other.
Source Fool.com
